Venture Capital and Strategic Advisory Services

R. Scott Greer, an entrepreneur with over 30 years experience in the biotechnology industry, founded Numenor Ventures LLC to provide funding and advisory services to early stage companies. Mr. Greer was a founder, CEO, and Chairman of Abgenix, Inc., a biotechnology company he took public in 1998. Abgenix was sold to Amgen, Inc. in 2006 for in excess of $2.2 billion. He has served on numerous public and private boards. In addition, he is an investor and consultant to CEOs and /or founders of companies in various stages of development.

During the past fifteen years, the principals of Numenor Ventures have directly invested in over twenty start-up/early stage companies. A significant majority of Numenor Venture’s investments are in life science and technology companies. However, Numenor Ventures also invests in unique consumer product, fine art, and real estate opportunities.

Numenor Ventures does not consider or review unsolicited business plans or opportunities.

Representative Investments/Clients

Ablexis, LLC
Affymax, Inc. (public)
Alex Mertens Fine Art
Ambit, Inc. (public)
Anaptys Biosciences, Inc. (public)
Annovium, LLC (sold)
BAROnova, Inc.
Chimeros, Inc.
Calimmune, Inc. (sold)
Christopher Clark Fine Art
CV Therapeutics, Inc. (public)
Ensemble Discovery Corp.
Illumina, Inc. (public)
Inogen, Inc. (public)
Margate House, LLC
Nutricate Corp. (sold)
Noza, Inc. (sold)
Seamount Capital
Sirna, Inc. (sold)
Thuris, Inc.
Trubion, Inc. (sold)